Is it safe to deliver SBRT to progressive lung metastases to patients with metastatic RCC receiving concurrent pazopanib?

Generally speaking, yes, it’s safe with some caveats. Pazopanib is a bit of a “dirty” TK inhibitor and so has some VEGF inhibition. That has some implications if you are treating close to hollow viscous like the esophagus, stomach (if on the diaphragm) or trachea. If it’s just open lung, and not cen...

In our practice it has been safe to deliver SBRT to lung metastases while receiving drugs such as pazopanib given the thought that SBRT is more directed and associated with lower rates of pneumonitis.